Rockwell Medical, Inc. (NASDAQ:RMTI) Price Target Update - News Watch International PDF Print

Rockwell Medical, Inc. (NASDAQ:RMTI): 5 analysts have set the short term price target of Rockwell Medical, Inc. (NASDAQ:RMTI) at $16.6. The standard deviation of short term price target has been estimated at $7.99, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 26 and $4 respectively.

Many analysts have commented on the company rating. In a research note released to the investors, Bank of America reinstates its rating on Rockwell Medical, Inc. (NASDAQ:RMTI).The analysts at the brokerage house have a current rating of Neutral on the shares. The rating by the firm was issued on July 8, 2015. Research firm Zacks has rated Rockwell Medical, Inc. (NASDAQ:RMTI) and has ranked it at 3, indicating that for the short term the shares are a hold. 5 Wall Street analysts have given the company an average rating of 2.2. The shares have received a hold rating based on the suggestion from 1 analysts in latest recommendations. 1 brokerage houses have given a strong sell on the shares. Strong buy was given by 3 Wall Street Analysts. Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0% in the total insider ownership. Institutional Investors own 34.4% of Company shares. During last 3 month period, 25.61% of total institutional ownership has changed in the company shares. Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) ended Thursday session in red amid volatile trading. The shares closed down 2.2 points or 16.01% at $11.54 with 3,160,052 shares getting traded. Post opening the session at $12.23, the shares hit an intraday low of $11.25 and an intraday high of $12.67 and the price vacillated in this range throughout the day. The company has a market cap of $580 million and the number of outstanding shares have been calculated to be 50,223,000 shares. The 52-week high of Rockwell Medical, Inc. (NASDAQ:RMTI) is $18.8999 and the 52-week low is $8.095. Rockwell Medical, Inc. has lost 19.02% in the last five trading days and dropped 36.94% in the last 4 weeks. Rockwell Medical, Inc. is up 12.26% in the last 3-month period. Year-to-Date the stock performance stands at 12.26%. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. NO COMMENTS LEAVE A REPLY Cancel reply

...

 
Share |
Copyright © 2017 Global Dialysis. All Rights Reserved.